본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

Association of antidiabetic medication use, cognitive decline, and risk of cognitive impairment in older people with type 2 diabetes: Results from the population‐based Mayo Clinic Study of Aging

Wennberg, Alexandra M.V. (Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA ) ; Hagen, Clinton E. (Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA ) ; Edwards, Kelly (Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA ) ; Roberts, Rosebud O. (Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA ) ; Machulda, Mary M. (Department of Psychology, Mayo Clinic, Rochester, MN, USA ) ; Knopman, David S. (Department of Neurology, Mayo Clinic, Rochester, MN, USA ) ; Petersen, Ronald C. (Department of Neurology, Mayo Clinic, Rochester, MN, USA ) ; Mielke, Michelle M. (Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA ) ;
  • 초록  

    Objective To determine the cross‐sectional and longitudinal associations between diabetes treatment type and cognitive outcomes among type II diabetics. Methods We examined the association between metformin use, as compared to other diabetic treatment (ie, insulin, other oral medications, and diet/exercise) and cognitive test performance and mild cognitive impairment (MCI) diagnosis among 508 cognitively unimpaired at baseline type II diabetics enrolled in the Mayo Clinic Study of Aging. We created propensity scores to adjust for treatment effects. We used multivariate linear and logistic regression models to investigate the cross‐sectional association between treatment type and cognitive test z scores, respectively. Mixed effects models and competing risk regression models were used to determine the longitudinal association between treatment type and change in cognitive test z scores and risk of developing incident MCI. Results In linear regression analyses adjusted for age, sex, education, body mass index, APOE ε4, insulin treatment, medical comorbidities, number of medications, duration of diabetes, and propensity score, we did not observe an association between metformin use and cognitive test performance. Additionally, we did not observe an association between metformin use and cognitive test performance over time (median = 3.7‐year follow‐up). Metformin was associated with an increased risk of MCI (subhazard ratio (SHR) = 2.75; 95% CI = 1.64, 4.63, P P = .009) and insulin (SHR = 3.17; 95% CI = 1.27, 7.92; P = .014) use were also associated with risk of MCI diagnosis. Conclusions These findings suggest that metformin use, as compared to management of diabetes with other treatments, is not associated with cognitive test performance. However, metformin was associated with incident MCI diagnosis.


  • 주제어

    cognition .   metformin .   type II diabetes.  

 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.
유료다운로드

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기